Trial Profile

A Phase 3, Randomized Study of Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs Chemotherapy Alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel; Pemetrexed
Indications Brain metastases; Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms CheckMate 9LA
Sponsors Bristol-Myers Squibb

Most Recent Events

24 Dec 2024 Status changed from active, no longer recruiting to completed.
04 Jun 2024 Updated efficacy and safety data with a 5-y follow up (f/u) and outcomes in 5-y survivors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
03 Jun 2024 Results presented in a Bristol-Myers Squibb Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com